BeOne Medicines Ltd., previously known as BeiGene, is a fully integrated, global biotechnology company specializing in targeted and immuno-oncology therapies. The company's business model spans the entire drug development lifecycle, from internal discovery and clinical research to manufacturing and commercialization. BeOne's portfolio is anchored by two internally developed flagship products: Brukinsa (zanubrutinib), a small molecule Bruton's tyrosine kinase (BTK) inhibitor used to treat various hematologic malignancies, and Tevimbra (tislelizumab), an anti-PD-1 monoclonal antibody for solid tumors. Brukinsa is the company's primary revenue driver, generating blockbuster sales globally. In addition to its proprietary pipeline, which includes small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), and cell and gene therapies, BeOne commercializes oncology drugs in China through strategic partnerships with major pharmaceutical companies like Amgen and Novartis. Geographically, the company maintains a massive global footprint with operations across North America, Europe, and Asia, and conducts clinical trials in over 45 countries. A key competitive advantage for BeOne is its "CRO-free" clinical development strategy; by utilizing an expansive internal clinical operations team rather than relying on contract research organizations, the company aims to accelerate trial timelines and reduce costs. The company rebranded from BeiGene to BeOne Medicines in late 2024 and redomiciled from the Cayman Islands to Switzerland in May 2025.
